Skip to main content

Results from the Phase 3 iLLUMINATE Study: Ibrutinib + Obinutuzumab as First-Line Treatment in Patients with CLL/SLL

Conference Correspondent - ASH 2018 - Chronic Lymphocytic Leukemia
In iLLUMINATE, researchers investigated the potential for improved efficacy with the addition of obinutuzumab to single-agent ibrutinib versus chlorambucil-obinutuzumab. iLLUMINATE is the first study to prospectively evaluate a chemotherapy-free regimen versus chemoimmunotherapy in high-risk chronic lymphocytic leukemia (CLL) patients. Eligible CLL patients required treatment and were at least 65 years of age or less than 65 years of age with ≥1 of the following: cumulative illness rating score >6, creatinine clearance <70 mL/min, and/or del(17p) or TP53 mutation. Patients were randomized 1:1 to receive ibrutinib (420 mg once daily continuously) combined with obinutuzumab (1000 mg for 6 cycles), or chlorambucil (0.5 mg/kg for 6 cycles) combined with obinutuzumab. The primary study end point was progression-free survival (PFS) and secondary end points included PFS in high-risk patients, rate of undetectable minimal residual disease (MRD), overall response rate (ORR), overall survival (OS), and safety. Patients with confirmed progression were permitted to cross over to next-line therapy with ibrutinib. A total of 229 patients were randomized to ibrutinib-obinutuzumab (n = 113) or chlorambucil-obinutuzumab (n = 116). The median age was 71 years and about two-thirds (65%) of patients had high-risk genomic features.

At a median follow-up of 31.3 months, the median PFS by independent review committee assessment was not reached for ibrutinib-obinutuzumab compared with 19.0 months for chlorambucil-obinutuzumab (P <.0001). This finding translates to a 74% reduction in risk for progression or death. PFS rates at 30 months were 79% and 31% with ibrutinib-obinutuzumab and chlorambucil-obinutuzumab, respectively. Furthermore, PFS benefit with ibrutinib-obinutuzumab was consistent across the high-risk subgroups examined, which included patients with del(17p)/TP53 mutation, del(11q), and/or unmutated IGHV. Similarly, ORRs and complete response rates were higher with ibrutinib-obinutuzumab versus chlorambucil-obinutuzumab. MRD was undetectable in blood and/or bone marrow for 35% of patients with ibrutinib-obinutuzumab versus 25% with chlorambucil-obinutuzumab. OS rates with median follow-up of 31 months were statistically similar for the 2 groups; however, it should be noted that 40% of patients randomized to chlorambucil-obinutuzumab crossed over to single-agent ibrutinib as second-line therapy.

In the ibrutinib-obinutuzumab arm, grade ≥3 adverse events included neutropenia (28%) and thrombocytopenia (18%), whereas in the chlorambucil-obinutuzumab arm, grade ≥3 neutropenia and thrombocytopenia rates were 46% and 10%, respectively. Grade ≥3 atrial fibrillation occurred in 3% of ibrutinib-obinutuzumab patients; no grade ≥3 atrial fibrillation was reported in the chlorambucil-obinutuzumab arm. Infusion-related reactions occurred more frequently in the chlorambucil-obinutuzumab arm (8% vs 2%). These adverse event rates were seen despite the fact that median duration of treatment was 29.3 months for patients treated with ibrutinib-obinutuzumab versus 5.1 months for chlorambucil-obinutuzumab.

Ibrutinib-obinutuzumab resulted in superior PFS regardless of high-risk genomic features compared with chlorambucil-obinutuzumab. Furthermore, response rates and depth of remission (complete response and undetectable MRD) were higher with ibrutinib-obinutuzumab. No new safety signals emerged. Researchers concluded that ibrutinib-obinutuzumab represents an effective chemotherapy-free treatment option for first-line CLL/SLL, including the high-risk population.

Moreno C, et al. ASH 2018. Abstract 691.

Related Items
Cost-Effectiveness Comparison of Ibrutinib, Chemotherapy, and Chemoimmunotherapy in First-Line Treatment of CLL
Conference Correspondent published on December 4, 2018 in ASH 2018 - Chronic Lymphocytic Leukemia
ECOG-ACRIN Cancer Research Group: Phase 3 Study of Ibrutinib-Based Therapy in Untreated Younger Patients with CLL
Conference Correspondent published on December 4, 2018 in ASH 2018 - Chronic Lymphocytic Leukemia
Prognostic Testing and Treatment Approaches in Patients with CLL: Interim Analysis of the informCLL Real-World Registry
Conference Correspondent published on December 4, 2018 in ASH 2018 - Chronic Lymphocytic Leukemia
Acalabrutinib in Patients with Relapsed/Refractory and High-Risk, Treatment-Naïve CLL
Conference Correspondent published on December 4, 2018 in ASH 2018 - Chronic Lymphocytic Leukemia
Frontline Ibrutinib Treatment Is Associated with Lower Total Cost of Care Compared with Chemoimmunotherapy in Patients with CLL
Conference Correspondent published on December 2, 2018 in ASH 2018 - Chronic Lymphocytic Leukemia
Last modified: August 30, 2021